Co-incidentally, ATO is currently undergoing multiple clinical trials in patients with a variety of different types of TP53 mutated cancers, including ovarian cancer (ClinicalTrials.gov Identifier, NCT04489706), endometrial cancer (ClinicalTrials.gov Identifier, NCT04489706), a basket trial in patients with diverse refractory solid tumours (NCT04869475) as well as in patients with various types of leukemia (ClinicalTrials.gov Identifier, NCT03381781; ClinicalTrials.gov Identifier: NCT03377725). This evidence concerns the gene TP53 and ovarian cancer.